Recursion Pharmaceuticals, Inc.

NASDAQ:RXRX

Biotechnology

Healthcare
$2.83 +1.45%

+$0.04 today

Market cap
$1.76B
Beta
1.00
P/E (TTM)
-3.0
EPS (TTM)
-$1.06
52W Low $2.77High $7.18

Volume 41.13M

Average 15.60M

RXRX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Recursion Pharmaceuticals, Inc.NASDAQ: RXRX

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin narrows to -49.8%

Gross margin was -49.8% in Q2 FY2026, down 44.3 pp from a year earlier. On a trailing-twelve-month basis it was -46.7%, down 42.9 pp year over year. Over 3 fiscal years it narrowed by 40.3 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-49.8%+43.2 pp QoQ
Last fiscal yearDec 2025
-62.0%-85.1 pp YoY
LTMJun 2026
-46.7%-42.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-44.3 pp——
1 year-85.1 pp——
3 years-40.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
-62.0%
Year-over-year change
-85.1pp

Gross Margin vs competitors

How RXRX compares with its peers on the latest reported figures

  • RXRX's LTM Jun 2026 gross margin of -46.7% is the 2nd highest of the 4 companies compared; the peer median is -61.0%.
  • Its year-over-year change of -42.9 pp is the lowest of 3, against a peer median of +874.5 pp.
  • Over three fiscal years its change of -40.3 pp compares with a peer median of +17573.1 pp.
RXRX Competitors Peer median
Gross Margin for RXRX and competitors
Company Period LTM level YoY 3-year change
MAZEMaze Therapeutics, Inc.LTM Mar 202692.0% -8.0 pp—
RXRXRecursion Pharmaceuticals, Inc.LTM Jun 2026-46.7% -42.9 pp-40.3 pp
DNLIDenali Therapeutics Inc.LTM Jun 2026-61.0% ——
RLAYRelay Therapeutics, Inc.LTM Jun 2026-566.6% +1757.0 pp+17573.1 pp
Peer median (excluding RXRX) -61.0%+874.5 pp+17573.1 pp

Competitors are the stored peer set for RXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10M39.68M43.88M58.84M74.68M
Cost of Revenue048.28M42.59M45.24M120.95M
Gross Profit10M(8.59M)1.29M13.6M(46.27M)
Gross Margin100.0%-21.7%2.9%23.1%-62.0%
Research & Development135.27M155.7M241.23M314.42M425.27M
Selling, General & Admin57.68M81.6M110.82M178.18M176.59M
Operating Expenses192.78M237.13M351.35M492.61M601.86M
Depreciation & Amortization8.41M11.76M24.4M36.49M83.7M
EBITDA(175.12M)(227.67M)(307.63M)(426.72M)(559.38M)
EBITDA Margin-1751.2%-573.7%-701.1%-725.2%-749.0%
Operating Income(182.78M)(245.73M)(350.06M)(479M)(648.13M)
Operating Margin-1827.8%-619.3%-797.8%-814.1%-867.9%
Interest Income73K6.25M19.12M15.76M22.79M
Interest Expense2.95M55K97K1.57M1.81M
Other Income / Expenses(3.7M)6.25M17.93M14.22M3.24M
Income Before Tax(186.48M)(239.48M)(332.13M)(464.79M)(644.9M)
Pre-Tax Margin-1864.8%-603.5%-757.0%-789.9%-863.5%
Income Tax Expense00(4.06M)(1.13M)(136K)
Net Income(186.48M)(239.48M)(328.07M)(463.66M)(644.76M)
Net Margin-1864.8%-603.5%-747.7%-788.0%-863.4%
EPS (Basic)(1.05)(1.36)(1.58)(1.69)(1.44)
EPS (Diluted)(1.05)(1.36)(1.58)(1.69)(1.44)
Weighted Avg Shares170.27M175.54M207.85M274.21M447.45M
Weighted Avg Shares (Diluted)170.27M175.54M207.85M274.21M447.45M

Recursion Pharmaceuticals, Inc.

NASDAQ:RXRX

Intrinsic Alpha fair value

Locked

Current Price

$2.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.